leucine rich repeats and IQ motif containing 1Genealiases: []
Q-omics provides the consensus-scored LRRIQ1 profile across patient tissues and cancer cell-line models. LRRIQ1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, LRRIQ1 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, LRRIQ1 RNA expression shows 17,787 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight LGG, KICH, and KIRP as cancer lineages where LRRIQ1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRIQ1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRIQ1 survival associations across molecular data types. LRRIQ1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRIQ1 RNA expression–survival associations across cancer types. High LRRIQ1 expression shows unfavorable associations in LGG, STAD and LIHC, but favorable associations in BRCA, UCS and KIRP. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for LRRIQ1 RNA expression.
This table summarizes LRRIQ1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LRRIQ1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRIQ1 shows lower tumor expression in KICH, THCA, LUSC, KIRC and LUAD and higher tumor expression in PRAD. The KICH box plot shows higher LRRIQ1 RNA expression in normal versus tumor tissue (log2 FC = −1.424, t-test p < 0.001).
This table shows molecular features associated with LRRIQ1 in patient tissues and cancer cell lines. In patient samples, LRRIQ1 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRIQ1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LARGE_INTESTINE.
